Optimize and Predict Antidepressant Efficacy for Patient With MDD Using Multi-omics Analysis and AI-predictive Tool

Summary

OPADE is a non-profit, observational, multicenter, open-label study aimed at defining personalized treatment for Major Depressive Disorder (MDD). In particular, we will combine genetics, epigenetics, microbiome, immune response data together with anamnesis, questionnaires, electroencephalography (EEG) collected from subjects suffering MDD. Eventually, an Artificial Intelligence (AI)/Machine Learning (ML) predictive tool will be created to guide clinicians in improving MDD treatment and patient's stratification.

Conditions

• Major Depressive Disorder

Sponsors & Collaborators

• University of Siena

  collaborator OTHER

• Fundació Eurecat

  collaborator OTHER

• Perseus Biomics

  collaborator UNKNOWN

• ARTIFICIAL INTELLIGENCE EXPERT SRL

  collaborator INDUSTRY

• Mama Health Technologies GmbH

  collaborator INDUSTRY

• Protobios OU

  collaborator UNKNOWN

• Cephalgo

  collaborator INDUSTRY

• Biokeralty Research Institute

  collaborator INDUSTRY

• Sanitas University

  collaborator OTHER

• Accare

  collaborator OTHER

• Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

  collaborator OTHER

• Istanbul Medipol University Hospital

  collaborator OTHER

• CEINGE

  collaborator UNKNOWN

• Fondazione di ricerca biomedica EBRIS

  collaborator UNKNOWN

• Alessio Fasano

  lead OTHER

Eligibility

Min Age

14 Years

Max Age

50 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-08-07

Primary Completion

2027-04-30

Completion

2027-05-31

Countries

• Italy

Study Locations